CRISPR Therapeutics AG (CRSP)
55.69
-1.07
(-1.89%)
USD |
NASDAQ |
Apr 16, 16:00
55.64
-0.05
(-0.09%)
After-Hours: 20:00
CRISPR Therapeutics Enterprise Value : 3.671B for April 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 107.63B |
| Novartis AG | 314.40B |
| EvoNext Holdings SA | -- |
| Kuros Biosciences Ltd. | 1.086B |
| Basilea Pharmaceutica AG | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -130.61M |
| Revenue (Quarterly) | 0.864M |
| Total Expenses (Quarterly) | 131.48M |
| EPS Diluted (Quarterly) | -1.371 |
| Gross Profit Margin (Quarterly) | -6.77K% |
| Profit Margin (Quarterly) | -15.12K% |
| Earnings Yield | -11.70% |
| Normalized Earnings Yield | -10.46 |